Copyright ©The Author(s) 2015.
World J Biol Chem. Aug 26, 2015; 6(3): 162-208
Published online Aug 26, 2015. doi: 10.4331/wjbc.v6.i3.162
Table 6 Validated myomiR targets related to cancer progression
Up regulated cell factorDown regulated cell factorCancer typeRef.
Downregulated myomiRs
Downregulated miR-1
Mediator complex subunit 1 (Med1) and 31 (Med31) upregulatedmiR-1 downregulatedOsteosarcoma[257]
Slug expression upregulated; enhanced cell migratory and invasive activitiesmiR-1 downregulatedChordoma[261]
Slug expression upregulated; stimulation of EMT processmiR-1 reduced increasingly with cancer progressionProstate adenocarcinoma[321]
Downregulated miR-133a
ARPC5 upregulated;Downregulated miR-133a (> miR-206)Lung SCC[115]
CAV1 upregulated;miR-133a downregulatedHNSCC[322]
Moesin upregulated;miR-133a downregulatedHNSCC[143]
FSCN1 upregulated;miR-133a/ miR-133b downregulatedESCC[132]
Bladder cancer (TCC)[274]
GSTP1 upregulated;miR-133a downregulatedHNSCC[323]
Bladder cancer (TCC)[144]
Lung SCC[115]
LASP1 upregulated;miR-133a downregulated in 83% of colorectal tumorsColorectal cancer[136]
CAV1 downregulated with miR-133a levels, and is lowest in metastatic cancers;Contrastingly, higher levels of miR-133a correlate with poor prognosis and increased metastasis
FSCN1 upregulated in non-metastatic tumors
LASP1 upregulated;miR-133a downregulatedBladder cancer (TCC)[313]
PKM2 upregulated;miR-133a downregulatedTSCC[111]
Moesin upregulated;miR-133a downregulatedHNSCC[143]
EGFR upregulated;miR-133 downregulatedHormone-sensitive prostate cancer cell lines[324]
Human TERT telomerase catalytic subunit upregulated;miR-133a downregulated[325]
TCF7 transcription factor upregulated;miR-133a downregulated[325]
FSCN1 and MMP14 upregulated;miR-133a downregulatedESCC[326]
Reduced miR-133a expression correlated significantly with advanced clinical stages, poor histological differentiation and lymph node metastasisMarked downregulation of miR-133a in primary EOC tumors and OVCAR-3 cell lineEpithelial ovarian cancer (EOC), and in OVCAR-3 cell line[327]
Downregulated miR-133b
FSCN1 upregulated;miR-133a/-133b downregulatedESCC[132]
FSCN1 mRNA upregulated;miR-133b downregulatedProgressive GIST[281]
BCL2L2 upregulated;miR-133b downregulatedLung cancer[85]
MCL1 upregulated;miR-133b downregulatedLung cancer[85]
MET upregulated;miR-133b downregulatedColorectal cancer[87]
MET protein upregulated;miR-133b downregulatedhigh grade osteosarcoma tumor samples and cell lines[328]
EGFR upregulated;miR-133b downregulatedNSCLC[105]
Multiple cell factors elevated;miR-133b downregulatedProstate cancer[282]
FGFR1 downregulated;miR-133b downregulatedGastric cancer[329]
Gli1 protein downregulated by miR133b, Gli1 target genes, OPN and Zeb2, are indirectly regulatedmiR-133b downregulatedGastric cancer[283]
TAp63 supresses metastasis; downregulation target of miR-133bmiR-133b is a transcription target of TAp63, downregulatedColon cancer cells[330]
Chemokine (C-X-C motif) receptor 4 protein downregulated by miR133b; upregulated in advanced cancermiR-133b downregulatedCRC[331]
TBP-like 1 mRNA and protein are upregulated in CRCmiR-133b downregulated in CRCCRC[332]
Strong additional down regulation of miR-133b aids liver metastatic niche for CRC cellsmiR-133b downregulated 3 × (significant) in liver metastasis compared to primary CRCmiR-133b downregulated in primary CRC compared to surrounding tissueMetastatic cancer arising from primary hCRC[333]
Interestingly, miR-133b is not downregulated significantly in lung metastasis compared to primary CRC
SP1 targeted directly by miR-133, causing reduced expression of MMP-9 and Cyclin D1miR-133a and -133b downregulatedGastric cancer[334]
miR-133b target MMP-9 is upregulatedmiR-133b downregulatedRCC[335]
Downregulated miR-206
ERαERα downregulates miR-206ERα-positive breast cancer;[294]
miR-206 downregulatedDouble feedback loop[109]
miR-206 downregulated[293,336]
ERαmiR-206 downregulatedEEC tissue[110]
SRC-1, SRC-3 and GATA-3 proteins contribute to estrogenic signallingmiR-206 downregulatedERα-positive breast cancer[296]
Signalling contributes to Luminal-A phenotype
KLF4 over expressed in proliferating cells and cancers.miR-206 levels are KLF4 dependent. KLF4 and miR-206 feedback pathway oppositely affect KLF4 protein translationBreast cancer cells and normal cells[108]
FGBP1miR-206 gene double knockdownmiR-206-/- mouse skeletal muscle.[12]
VEGF upregulatedmiR-206 downregulatedLaryngeal SCC cells[113]
VEGF upregulatedmiR-206 downregulatedCRC tumors compared to matched normal tissue; (1DS assay)[337]
miR-206 correlates with negative ER status, negative PR status, and negative HER-2 statusDownregulated miR-206Breast cancer tumor tissue[338]
miR-206 was downregulated in clinical TNBC tumor samples, one of its targets, actin-binding protein coronin was upregulatedDownregulated miR-206 associates with increased metastasis potential in breast cancersHigh metastatic capacity TNBC tumors[305]
Downregulated miR-1 and miR-133a
PNP upregulatedmiR-1/miR-133a downregulatedMSSCC[137]
Prostate cancer[97]
Bladder cancer (TCC)[312]
TAGLN2 upregulated;miR-1/miR-133a downregulatedMSSCC;[137]
Bladder cancer (TCC)[93]
PTMA upregulatedmiR-1 and miR-133a downregulatedBladder cancer (TCC)[312]
Downregulated miR-1 and miR-206
MET levels correlated inversely with miR-1/206 expressionmiR-1/206 downregulatedUp-regulation of MET in rhabdomyosarcoma[89,288]
HGFR upregulatedmiR-1/206 downregulatedBreast cancer cells[289]
G6PD; PGD; TKT; GPD2 upregulatedmiR-1/206 downregulatedPrimary lung adenocarcinoma[99]
Upregulated myomiRs
Upregulated miR-133b
miR-133bmiR-133b strongly upregulatedMST1, CDC42, RHOA, and DUSP1 downregulatedCervical carcinoma[121]
miR-133bmiR-133b is directly upregulated by ARmiR-133b represses CDC2L5, PTPRK, RB1CC1, and CPNE3PCa prostate cancer cell line[123]
Upregulated miR-206
miR-206Strongly upregulated miR-206KLF4 downregulatedHuman colon cancer tissue[116]
Upregulated miR-1 and miR-133a
miR-1-2 and miR-133-a-1Upregulated miR-1-2 and miR-133-a-1EVI1 (transcriptional activator of miR-1 and miR-133b)AML[120,151]
miR-1 and miR-133-aUpregulated miR-1 and miR-133-aDownregulated CCND2Multiple myeloma[152]
Up-regulation of exogenous myomiR expression in cell lines
Reduced cell proliferationEstrogen receptor alphaOverexpression of miR-206 has an inhibitory effect on cell proliferationERα-positive breast cancer cells over expressing mir-206[289]
miR-133bGSTP1 downregulatedTransgenic miR-133b overexpressionHeLa cervical cancer cells[282]
miR-133bFAIM downregulatedTransgenic miR-133b overexpressionHeLa cervical cancer cells[282]
Apoptosis increasedTNFα-induced cell death is activatedTransgenic miR-133b overexpressionHeLa cervical cancer cells[282]
Increased cell proliferation and migrationDownregulation of MST2Transgenic miR-133b overexpressionCaSki cervical cancer cells[121]
Downregulation of CDC42
Downregulation of RHOA
Increased cell proliferation and migrationIndirect upregulation of p-AKT1 activityTransgenic miR-133b overexpressionCaSki cervical cancer cells[121]
Indirect upregulation of p-ERK activity
RB1CC1 downregulatedExogenous upregulation of miR-133b;miR-133bm promotes cell apoptosis, but suppressed cell proliferation and cell-cycle progression in aggressive PC-3 cellsPC3 prostate cancer cell line[106]
miR-133b directly targets RB1CC1 in LNCaP cellsIn contrast in low-aggression LNCaP cells, miR-133b stimulate cell proliferation and cell-cycle progression, but inhibit apoptosisHormone sensitive prostate cancer LNCaP cell line
Cell proliferation decreased and apoptosis increasedMet, Twf1 and Ets1 and Bag4 activities downregulatedmiR-1 expression is lower in mouse cSCCs compared to normal skinMouse cutaneous squamous cell carcinomas (cSCCs); A5 and B9 cSCCcell lines[256]
Transgenic miR-1 overexpression
Ets1 proto-oncogeneRepression of Ets1 expression inhibited HepG2 cell invasion and migrationTransgenic miR-1 overexpressionHCC HepG2 cells[340]
lncRNA UCA1Knockdown of lnc UCA1 expression phenocopied the effects of upregulation of hsa-miR-1hsa-miR-1 decreased the expression of lnc UCA1 in bladder cancer cells in an Ago2-slicer-dependent mannerHuman bladder cancer (TCC) cells[156]
NOTCH3 signallingmiR-206 had a direct inhibition of NOTCH3 signalling and indirect interaction with other signalling pathways via CDH2 and MMP-9miR-206 upregulation blocks the cell cycle, inhibits cancer cell proliferation and migration and activates cell apoptosisSW480 (plus its metastatic strain) and SW620 colon cancer cell lines[341]
FSCN1miR-133b targets FSCN1 in GC cells; the direct knockdown of FSCN1 can also inhibit GC cell growth and invasionUp regulation of miR-133b in GC cells inhibits cell proliferation, cell migration and invasionmiR-133b is significantly downregulated in GC tissues compared with adjacent normal tissues, as well as in GC cell lines[342]
FSCN1miR-133a targets FSCN1 in CRC cells;Up regulation of miR-133a expression and downregulation of FSCN1 protein expression both suppress colorectal cancer cell invasionmiR-133a is significantly downregulated in some colorectal cancer cell lines, as well as in colorectal cancer tissues compared with the normal adjacent tissues[343]
Overexpression of FSCN1 can reverse the inhibitory effect of miR-133a upregulation, reactivating CRC cell invasion